label
 1.14LabelingHIGHLIGHTSOFPRESCRIBINGINFORMATIONThesehighlightsdonotincludealltheinformationneededtouseMarqibo(vinCRIStinesulfateLIPOSOMEinjection)safelyandeffectively.SeeFullPrescribingInformationforMarqibo(vinCRIStinesulfateLIPOSOMEinjection). Marqibo(vinCRIStinesulfateLIPOSOMEinjection)forintravenousinfusionInitialU.S.Approval:2012 WARNINGSee full prescribing information for complete boxed warning. x ForIntravenousUseOnly&#x2013;FatalifGivenbyOtherRoutes(5.1)x Deathhasoccurredwithintrathecalusex  Marqibo(vinCRIStinesulfateLIPOSOMEinjection)hasdifferent dosagerecommendationsthanvinCRIStinesulfateinjection.Verifydrugnameanddosepriortopreparationandadministrationtoavoidoverdosage. INDICATIONSANDUSAGEMarqiboisavincaalkaloidindicatedforthetreatmentofadultpatientswithPhiladelphiachromosomenegative(Ph)acutelymphoblasticleukemia(ALL)insecondorgreaterrelapseorwhosediseasehasprogressedfollowingtwoormoreantileukemiatherapies.
Thisindicationisbasedonoverallresponserate.Clinicalbenefitsuchasimprovementinoverallsurvivalhasnotbeenverified(1.1). DOSAGEANDADMINISTRATIONIntravenoususeonly.Donotadministerbyanyotherroute(2)AdministerMarqiboatadoseof2.25mg/m2intravenouslyover1houronceevery7days(2.1). DOSAGEFORMSANDSTRENGTHSThefinaldrugproductispreparedonsitefromthecomponentsintheMarqiboKit.Afterpreparation,eachsingledosevialofMarqibo(vinCRIStinesulfateLIPOSOMEinjection)contains5mg/31mL(0.16mg/mL)vincristinesulfate(2.3.2). CONTRAINDICATIONSx  Marqiboiscontraindicatedinpatientswithdemyelinatingconditions includingCharcotMarieToothsyndrome(4)x Marqiboiscontraindicatedinpatientswithhypersensitivityto vincristinesulfateoranyoftheothercomponentsofMarqibo(vinCRIStinesulfateLIPOSOMEinjection)(4) x  Marqiboiscontraindicatedforintrathecaladministration(4) WARNINGSANDPRECAUTIONSx Intrathecaladministrationisfatal(5.1) x Extravasationcausestissueinjury(5.2) x Neurologictoxicity:Monitorpatientsforperipheralmotorandsensory,
  centralandautonomicneuropathy,andreduce,interrupt,ordiscontinuedosing.PatientswithpreexistingsevereneuropathyshouldbetreatedwithMarqiboonlyaftercarefulriskbenefitassessment(2.2,5.3) x  Myelosuppression:MonitorbloodcountspriortoeachdoseofMarqibo.Neutropenia,thrombocytopenia,oranemiamayoccur;considerMarqibodosereductionorinterruptionandsupportivecaremeasures(5.4) x Tumorlysissyndrome:Anticipate,monitorfor,andmanage(5.5)x Constipation,bowelobstruction,and/orparalyticileus: Institutea prophylacticbowelregimentopreventpotentialconstipation,bowelobstruction,and/orparalyticileus(5.6) x Fatigue: Severefatiguecanoccur(5.7)x Hepatictoxicity: Monitorliverfunctionandmodifyorinterrupt dosing(5.8)x Embryofetaltoxicity:Cancausefetalharm.Advisewomenofpotential risktothefetus(5.9,8.1) ADVERSEREACTIONSMostcommonlyreportedadversereactions(incidence&#x2265;30%)inclinicalstudiesincludeconstipation,nausea,pyrexia,fatigue,peripheralneuropathy,febrileneutropenia,diarrhea,anemia,decreasedappetite,andinsomnia(6.1). ToreportSUSPECTEDADVERSEREACTIONS,contactTalonTherapeuticsat18882929617orFDAat1800FDA1088orwww.fda.gov/medwatch. DRUGINTERACTIONSMarqiboisexpectedtointeractwithdrugsknowntointeractwithnonliposomalvincristinesulfate(7). USEINSPECIFICPOPULATIONSPediatricUse:ThesafetyandeffectivenessofMarqiboinpediatricpatientshasnotbeenestablished(8.4) See17forPATIENTCOUNSELINGINFORMATION.     Revised:[July/2012 FULLPRESCRIBINGINFORMATION:CONTENTS WARNING: FORINTRAVENOUSUSEONLY 1  INDICATIONSANDUSAGE1.1 AdultALLinSecondorGreaterRelapse 2  DOSAGEANDADMINISTRATION2.1  RecommendedDosage2.2  Dosemodifications: PeripheralNeuropathy2.3  PreparationandHandling 3 DOSAGEFORMSANDSTRENGTHS4 CONTRAINDICATIONS5 WARNINGSANDPRECAUTIONS 5.1  ForIntravenousUseOnly5.2  ExtravasationTissueInjury5.3  NeurologicToxicity5.4  Myelosuppression 5.5  TumorLysisSyndrome5.6  ConstipationandBowelObstruction5.7  Fatigue5.8  HepaticToxicity5.9  EmbryofetalToxicity 6  ADVERSEREACTIONS6.1 ClinicalTrialsSafetyExperience 7  DRUGINTERACTIONS7.1  CYP3AInteractions7.2 PglycoproteinInteractions 8  USEINSPECIFICPOPULATIONS8.1  Pregnancy8.3  NursingMothers8.4  PediatricUse8.5  GeriatricUse8.6  RenalImpairment8.7  HepaticImpairment Reference ID: 3172211
 1  1.14Labeling10 OVERDOSAGE 15 REFERENCES11 DESCRIPTION 16 HOWSUPPLIED/STORAGEANDHANDLING 16.1 Storage12 CLINICALPHARMACOLOGY12.1 MechanismofAction 17 PATIENTCOUNSELINGINFORMATION12.3 Pharmacokinetics 13 NONCLINICALTOXICOLOGY*Sectionsorsubsectionsomittedfromthefullprescribinginformationarenot13.1 Carcinogenesis,Mutagenesis,ImpairmentofFertility listed.
13.2 AnimalToxicologyand/orPharmacology 14 CLINICALSTUDIES14.1 AcuteLymphoblasticLeukemia Reference ID: 3172211
 2                 1.14Labeling FULLPRESCRIBINGINFORMATIONWARNING x  ForIntravenousUseOnly-FatalifGivenbyOtherRoutes[see Warnings and Precautions (5.1)].x  Deathhasoccurredwithintrathecaladministration.x  Marqibo(vinCRIStinesulfateLIPOSOMEinjection)hasdifferentdosagerecommendationsthan vinCRIStinesulfateinjection.Verifydrugnameanddosepriortopreparationandadministrationtoavoidoverdosage. 1 INDICATIONSANDUSAGE1.1 AdultALLinSecondorGreaterRelapseMarqiboisindicatedforthetreatmentofadultpatientswithPhiladelphiachromosomenegative(Ph)acutelymphoblasticleukemia(ALL)insecondorgreaterrelapseorwhosediseasehasprogressedfollowingtwoormoreantileukemiatherapies.Thisindicationisbasedonoverallresponserate.Clinicalbenefitsuchasimprovementinoverallsurvivalhasnotbeenverified. 2 DOSAGEANDADMINISTRATIONForIntravenousUseOnly. FatalifGivenbyOtherRoutes. Marqibo(vinCRIStinesulfateLIPOSOMEinjection)hasdifferentdosagerecommendationsthanvincristinesulfateinjection. Verifydrugnameanddosepriortopreparationandadministrationtoavoidoverdosage. 2.1 RecommendedDosageTherecommendeddoseofMarqibois2.25mg/m2intravenouslyover1houronceevery7days. Marqiboisliposomeencapsulatedvincristine. 2.2 Dosemodifications: PeripheralNeuropathyMarqiboiscontraindicatedinpatientswithdemyelinatingconditionsincludingCharcotMarieToothsyndrome[see Contraindications (4)]. PatientswithpreexistingsevereneuropathyshouldbetreatedwithMarqiboonlyaftercarefulriskbenefitassessment[see Warnings and Precautions (5.3)]. Fordoseorschedulemodificationsguidelinesforpatientswhoexperienceperipheralneuropathy,seeTable1. Reference ID: 3172211
 3                                        1.14Labeling Table1. RecommendedDoseModificationsforMarqiborelatedPeripheralNeuropathySeverityofPeripheralNeuropathySignsandSymptomsa ModificationofDoseandRegimenIfthepatientdevelopsGrade3(severesymptoms; InterruptMarqibo. limitingselfcareactivitiesofdailyliving[ADL]b) IftheperipheralneuropathyremainsatGrade3or orpersistentGrade2(moderatesymptoms;limiting 4,discontinueMarqibo. instrumentalADLc)peripheralneuropathy:  IftheperipheralneuropathyrecoverstoGrade1 or2,reducetheMarqibodoseto2mg/m2.IfthepatienthaspersistentGrade2peripheral InterruptMarqiboforupto7days. neuropathyafterthefirstdosereductionto IftheperipheralneuropathyincreasestoGrade3 2mg/m2: or4,discontinueMarqibo.
  IfperipheralneuropathyrecoverstoGrade1,reducetheMarqibodoseto1.825mg/m2. IfthepatienthaspersistentGrade2peripheral InterruptMarqiboforupto7days. neuropathyaftertheseconddosereductionto IftheperipheralneuropathyincreasestoGrade3 1.825mg/m2: or4,discontinueMarqibo. IfthetoxicityrecoverstoGrade1,reducetheMarqibodoseto1.5mg/m2. a GradingbasedontheNationalCancerInstitute(NCI)CommonTerminologyCriteriaforAdverseEvents(CTCAE)v3.0. b SelfcareADL:referstobathing,dressingandundressing,feedingself,usingthetoilet,takingmedications,andnotbedridden. c InstrumentalADL: referstopreparingmeals,shoppingforgroceriesandclothes,usingtelephone,managingmoney,etc. 2.3 PreparationandHandling2.3.1  Items Required by the Pharmacy to Prepare Marqibo
 x MarqiboKitx Waterbatha x Calibratedthermometera(0Cto100C)x Calibratedelectronictimera x Sterileventingneedleorothersuitabledeviceequippedwithasterile0.2micronfilterx 1mLor3mLsterilesyringewithneedle,andx 5mLsterilesyringewithneedle. a Themanufacturerwillprovidethewaterbath,calibratedthermometer,andcalibratedelectronictimertothemedicalfacilityattheinitialorderofMarqiboandwillreplacethemevery2years. 2.3.2  Preparation Instructions for Marqibo (vinCRIStine sulfate LIPOSOME injection), 5 mg/31 mL (0.16 mg/mL)
 Proceduresforhandlinganddisposalofanticancerdrugsshouldbefollowed[see References (15)]. Reference ID: 3172211
 4                               1.14Labeling Call[18882929617]ifyouhavequestionsaboutthepreparationofMarqibo.Marqibotakesapproximately60to90minutestoprepare.ThepreparershouldhavededicateduninterruptedtimetoprepareMarqiboduetotheextensivemonitoringoftemperatureandtimerequiredforthepreparation. AseptictechniquemustbestrictlyobservedsincenopreservativeorbacteriostaticagentispresentinMarqibo.ThepreparationstepsofMarqibothatinvolvemixingtheSodiumPhosphateInjection,Sphingomyelin/CholesterolLiposomeInjection,andVinCRIStineSulfateInjectionmustbedoneinabiologicalsafetycabinetorbyestablishedpharmacysafetyproceduresforthepreparationofsterileinjectableformulationsandhazardousdrugs. However,thepreparationstepsthatinvolveplacementofthevialinthewaterbathmustbedoneoutsideofthesterilearea. Donotusewithinlinefilters.Donotmixwithotherdrugs. 1.
 Fillawaterbathwithwatertoalevelofatleast8cm(3.2inches)measuredfromthebottomandmaintainthisminimumwaterlevelthroughouttheprocedure.Thewaterbathmustremainoutsideofthesterilearea. 2.
 Placeacalibratedthermometerinthewaterbathtomonitorwatertemperatureandleaveitinthewaterbathuntiltheprocedurehasbeencompleted. 3.
 Preheatwaterbathto63Cto67C.Maintainthiswatertemperatureuntilcompletionoftheprocedureusingthecalibratedthermometer. 4.
 VisuallyinspecteachvialintheMarqiboKitforparticulatematteranddiscolorationpriortopreparation,wheneversolutionandcontainerpermit.Donotuseifaprecipitateorforeignmatterispresent. 5.
 Removeallthecapsonthevialsandswabthevialswithsterilealcoholpads.6.
 VenttheSodiumPhosphateInjectionvialwithasterileventingneedleequippedwithasterile0.2micron filterorothersuitableventingdeviceinthebiologicalsafetycabinet.AlwayspositionventingneedlepointwellaboveliquidlevelbeforeaddingSphingomyelin/CholesterolLiposomeInjectionandVinCRIStineSulfateInjection. 7.
 Withdraw1mLofSphingomyelin/CholesterolLiposomeInjection.8.
 Inject1mLofSphingomyelin/CholesterolLiposomeInjectionintotheSodiumPhosphateInjectionvial.9.
 Withdraw5mLofVinCRIStineSulfateInjection.10.Inject5mLofVinCRIStineSulfateInjectionintotheSodiumPhosphateInjectionvial.11.RemovetheventingneedleandgentlyinverttheSodiumPhosphateInjectionvial5timestomix.  DONOTSHAKE. 12.FitFlotationRingaroundtheneckoftheSodiumPhosphateInjectionvial.13.Confirmthatthewaterbathtemperatureisat63Cto67Cusingthecalibratedthermometer. Remove theSodiumPhosphateInjectionvialcontainingVinCRIStineSulfateInjection,Sphingomyelin/CholesterolLiposomeInjection,andSodiumPhosphateInjectionfromthebiologicalsafetycabinetandplaceintothewaterbathfor10minutesusingthecalibratedelectronictimer.Monitorthetemperaturetoensurethetemperatureismaintainedat63Cto67C. 14.IMMEDIATELYafterplacingtheSodiumPhosphateInjectionvialintothewaterbath,recordthe constitutionstarttimeandwatertemperatureontheMarqiboOverlabel.  15.Attheendofthe10minutes,confirmthatthewatertemperatureis63Cto67Cusingthecalibratedthermometer.Removethevialfromthewaterbath(usetongstopreventburns)andremovetheFlotationRing. 16.RecordthefinalconstitutiontimeandthewatertemperatureontheMarqiboOverlabel. Reference ID: 3172211
 5                             1.14Labeling 17.DrytheexterioroftheSodiumPhosphateInjectionvialwithacleanpapertowel,affixMarqibo (vinCRIStinesulfateLIPOSOMEinjection)Overlabel,andgentlyinvert5timestomix. DONOTSHAKE.  18.Permittheconstitutedvialcontentstoequilibrateforatleast30minutestocontrolledroomtemperature(15Cto30C,59Fto86F). 19.Marqibo(vinCRIStinesulfateLIPOSOMEinjection)contains5mg/31mL(0.16mg/mL)vincristinesulfate. ONCEPREPARED,STOREATCONTROLLEDROOMTEMPERATURE(15Cto30C,59Fto86F)FORNOMORETHAN12HOURS. 20.SwabthetopofthevialnowcontainingMarqibowithasterilealcoholpadandreturnthevialbackintothebiologicalsafetycabinet. 21.Calculatethepatient&#x2019;sMarqibodosebasedonthepatient&#x2019;sactualbodysurfacearea(BSA)andremovethevolumecorrespondingtothepatient&#x2019;sMarqibodosefromaninfusionbagcontaining100mLof5%DextroseInjectionor0.9%SodiumChlorideInjection. 22.InjectthedoseofMarqibointotheinfusionbagtoresultinafinalvolumeof100mL.23.CompletetheinformationrequiredontheInfusionBagLabelandapplytotheinfusionbag.24.Finishadministrationofthedilutedproductwithin12hoursoftheinitiationofMarqibopreparation.25.Empty,clean,anddrythewaterbathaftereachuse.26.Deviationsintemperature,time,andpreparationproceduresmayfailtoensureproperencapsulationof vincristinesulfateintotheliposomes.Intheeventthatthepreparationdeviatesfromtheinstructionsintheabovesteps,thecomponentsofthekitshouldbediscardedandanewkitshouldbeusedtopreparethedose. Parenteraldrugproductsshouldbeinspectedvisuallyforparticulatematteranddiscolorationpriortoadministration,wheneversolutionandcontainerpermit.Donotuseifaprecipitateorforeignmatterispresent. 3 DOSAGEFORMSANDSTRENGTHSMarqiboispreparedfromthecomponentsintheMarqiboKit.Followingthepreparationprocedureaccordingtosection2.3.2,eachsingledosevialofMarqibo(vinCRIStinesulfateLIPOSOMEinjection)contains5mg/31mL(0.16mg/mL)vincristinesulfate. 4 CONTRAINDICATIONSMarqiboiscontraindicatedinpatientswithdemyelinatingconditionsincludingCharcotMarieToothsyndrome. MarqiboiscontraindicatedinpatientswithhypersensitivitytovincristinesulfateoranyoftheothercomponentsofMarqibo(vinCRIStinesulfateLIPOSOMEinjection). Marqiboiscontraindicatedforintrathecaladministration. 5 WARNINGSANDPRECAUTIONS5.1 ForIntravenousUseOnlyFatalifGivenbyOtherRoutes. Deathhasoccurredwithintrathecaluse. 5.2 ExtravasationTissueInjuryOnlyadministerthroughasecureandfreeflowingvenousaccessline.Ifextravasationissuspected,discontinueinfusionimmediatelyandconsiderlocaltreatmentmeasures. 5.3 NeurologicToxicitySensoryandmotorneuropathiesarecommonandarecumulative.Monitorpatientsforsymptomsofneuropathy,suchashypoesthesia,hyperesthesia,paresthesia,hyporeflexia,areflexia,neuralgia,jawpain,decreasedvibratorysense,cranialneuropathy,ileus,burningsensation,arthralgia,myalgia,musclespasm,or Reference ID: 3172211
 6                             1.14Labeling weakness,bothbeforeandduringtreatment.Orthostatichypotensionmayoccur.TheriskofneurologictoxicityisgreaterifMarqiboisadministeredtopatientswithpreexistingneuromusculardisordersorwhenotherdrugswithriskofneurologictoxicityarebeinggiven.Inthestudiesofrelapsedand/orrefractoryadultALLpatients,Grade?3neuropathyeventsoccurredin32.5%ofpatients.Worseningneuropathyrequiresdosedelay,reduction,ordiscontinuationofMarqibo[see Dosage and Administration (2.2)].5.4 MyelosuppressionMonitorcompletebloodcountspriortoeachdoseofMarqibo.IfGrade3or4neutropenia,thrombocytopenia,oranemiadevelops,considerMarqibodosemodificationorreductionaswellassupportivecaremeasures. 5.5 TumorLysisSyndromeTumorlysissyndrome(TLS)mayoccurinpatientswithALLreceivingMarqibo.Anticipate,monitorfor,andmanage. 5.6 ConstipationandBowelObstructionIleus,bowelobstruction,andcolonicpseudoobstructionhaveoccurred.Marqibocancauseconstipation[see Adverse Reactions (6)]. Instituteaprophylacticbowelregimentomitigatepotentialconstipation,bowelobstruction,and/orparalyticileus,consideringadequatedietaryfiberintake,hydration,androutineuseofstoolsofteners,suchasdocusate. Additionaltreatments,suchassenna,bisacodyl,milkofmagnesia,magnesiumcitrate,andlactulosemaybeconsidered. 5.7 FatigueMarqibocancauseseverefatigue.Marqibodosedelay,reduction,ordiscontinuationmaybenecessary. 5.8 HepaticToxicityFatallivertoxicityandelevatedlevelsofaspartateaminotransferasehaveoccurred.ElevatedlevelsofaspartateaminotransferaseofGrade?3occurredin611%ofpatientsinclinicaltrials.Monitorhepaticfunctiontests.ReduceorinterruptMarqiboforhepatictoxicity. 5.9 EmbryofetalToxicityMarqibocancausefetalharmwhenadministeredtoapregnantwoman.Vincristinesulfateliposomeinjectionwasteratogenicorcausedembryofetaldeathinanimals.WomenofchildbearingpotentialshouldavoidbecomingpregnantwhilebeingtreatedwithMarqibo.TherearenoadequateandwellcontrolledstudiesofMarqiboinpregnantwomenandtherewerenoreportsofpregnancyinanyoftheclinicalstudiesintheMarqiboclinicaldevelopmentprogram.Ifthisdrugisusedduringpregnancy,orifthepatientbecomespregnantwhiletakingthisdrug,thepatientshouldbeapprisedofthepotentialhazardtoafetus[see Use in Specific Populations (8.1)].
 6 ADVERSEREACTIONSThefollowingadversereactionsarealsodiscussedinothersectionsofthelabeling: x Forintravenoususeonly[see Warnings and Precautions (5.1)]  x Extravasationtissueinjury[see Warnings and Precautions (5.2)] x PeripheralNeuropathy[see Warnings and Precautions (5.3)] x Myelosuppression[see Warnings and Precautions (5.4)] x Tumorlysissyndrome[see Warnings and Precautions (5.5)] x Constipationandbowelobstruction[see Warnings and Precautions (5.6)] x Fatigue[see Warnings and Precautions (5.7)] x Hepatictoxicity[see Warnings and Precautions (5.8)]  Reference ID: 3172211
 7     1.14Labeling 6.1 ClinicalTrialsSafetyExperienceBecauseclinicaltrialsareconductedunderwidelyvaryingconditions,adversereactionratesobservedintheclinicaltrialsofadrugcannotbedirectlycomparedtoratesintheclinicaltrialsofanotherdrugandmaynotreflecttheratesobservedinclinicalpractice. Integrated Summary of Safety in Relapsed and/or Refractory Ph- Adult Acute Lymphoblastic Leukemia Marqibo,atadoseof2.25mg/m2weekly,wasstudiedinatotalof83patientsintwotrials:study1andstudy2.Adversereactionswereobservedin100%ofpatients.Themostcommonadversereactions(&gt;30%)wereconstipation(57%),nausea(52%),pyrexia(43%),fatigue(41%),peripheralneuropathy(39%),febrileneutropenia(38%),diarrhea(37%),anemia(34%),decreasedappetite(33%),andinsomnia(32%). AdversereactionsofGrade3orgreaterwerereportedin96%ofpatients.AdversereactionsofGrade3orgreaterandoccurringin?5%ofpatientsaresummarizedinTable2. Reference ID: 3172211
 8             1.14Labeling Table2. MostCommonlyReported(&gt;5%)Gradea3orGreaterAdverseReactionsamong83PatientsReceivingtheClinicalDosingRegimen Study1and2AdverseReactionsGrade?3 (N=83) n(%)Blood and Lymphatic System Disorders  47 (56.6)
 FebrileNeutropenia 26(31.3)Neutropenia 15(18.1)Anemia 14(16.9)Thrombocytopenia 14(16.9) Infections  33 (39.8) Pneumonia 7(8.4)SepticShock 5(6.0)StaphylococcalBacteremia 5(6.0) Neuropathyb  27 (32.5) PeripheralSensoryandMotorNeuropathy 14(16.7) Constipation 4(4.8)  Ileus,ColonicPseudoObstruction 5(6.0) Asthenia 4(4.8)  MuscularWeakness 1(1.2)  Respiratory Thoracic and Mediastinal Disorders 17 (20.5) RespiratoryDistress 5(6.0) RespiratoryFailure 4(4.8)  General Disorders and Administration Site Condition 31 (37.3) Pyrexia 12(14.5)Fatigue 10(12.0)Pain 7(8.4) Gastrointestinal Disorders  21 (25.3) AbdominalPain 7(8.4) Investigations  20 (24.1) AspartateAminotransferaseIncreased 6(7.2) Vascular Disorders  8 (9.6) Hypotension  5(6.0) Psychiatric Disorders  9 (10.8) MentalStatusChanges 3(3.6) Cardiac Disorders  9 (10.8) CardiacArrest 5(6.0) Renal and Urinary Disorders 6 (7.2)  Musculoskeletal and Connective Tissue Disorders 7 (8.4)  a NationalCancerInstitute(NCI)CommonTerminologyCriteriaforAdverse Events(CTCAE)v3.0.b Includingneuropathyassociatedadversereactions. Atotalof75.9%ofpatientsexperiencedseriousadverseevents(SAEs)duringthestudies.ThemostcommonlyreportedSAEsincludedfebrileneutropenia(20.5%),pyrexia(13.3%),hypotension(7.2%),respiratorydistress(6.0%),andcardiacarrest(6.0%). Dosereduction,delay,oromissionoccurredin53%ofpatientsduringthetreatment. Twentyeightpercentofpatientsexperiencedadversereactionsleadingtotreatmentdiscontinuation.Themostcommonadversereactionsthatcausedtreatmentdiscontinuationwereperipheralneuropathy(10%),leukemiarelated(7%),andtumorlysissyndrome(2%). Reference ID: 3172211
 9               1.14Labeling Adversereactionsrelatedtoneuropathyandleadingtotreatmentdiscontinuationweredecreasedvibratorysense,facialpalsy,hyporeflexia,constipation,asthenia,fatigue,andmusculoskeletalpain,eachreportedinatleast1patient. Deathsoccurredin23%ofpatientsinstudy1.Thenonleukemiarelatedcausesofdeathswerebraininfarct(1),intracerebralhemorrhage(2),liverfailure(1),multisystemorganfailure(2),pneumoniaandsepticshock(3),respiratoryfailure(4),pulmonaryhemorrhage(1),andsuddencardiacdeath(1). 7 DRUGINTERACTIONSNoformaldruginteractionstudieshavebeenconductedwithMarqibo.Marqiboisexpectedtointeractwithdrugsknowntointeractwithnonliposomalvincristinesulfate. Simultaneousoralorintravenousadministrationofphenytoinandantineoplasticchemotherapycombinationsthatincludednonliposomalvincristinesulfatehavebeenreportedtoreducebloodlevelsofphenytoinandtoincreaseseizureactivity. 7.1 CYP3AInteractionsVincristinesulfate,theactiveagentinMarqibo,isasubstrateforcytochromeP4503Aisozymes(CYP3A);therefore,theconcomitantuseofstrongCYP3Ainhibitorsshouldbeavoided(e.g.,ketoconazole,itraconazole,voriconazole,posaconazole,clarithromycin,atazanavir,indinavir,nefazodone,nelfinavir,ritonavir,saquinavir,telithromycin).Similarly,theconcomitantuseofstrongCYP3Ainducersshouldbeavoided(e.g.,dexamethasone,phenytoin,carbamazepine,rifampin,rifabutin,rifapentine,phenobarbital,St.John&#x2019;sWort). 7.2 PglycoproteinInteractionsVincristinesulfate,theactiveagentinMarqibo,isalsoasubstrateforPglycoprotein(Pgp).TheeffectofconcomitantuseofpotentPgpinhibitorsorinducershasnotbeeninvestigated;itislikelythattheseagentswillalterthepharmacokineticsorpharmacodynamicsofMarqibo.ThereforetheconcomitantuseofpotentPgpinhibitorsorinducersshouldbeavoided. 8 USEINSPECIFICPOPULATIONS8.1 PregnancyPregnancyCategoryD[see Warnings and Precautions (5.9)]Basedonitsmechanismofactionandfindingsfromanimalstudies,Marqibocancausefetalharmwhenadministeredtopregnantwomen. Ifthisdrugisusedduringpregnancy,orifthepatientbecomespregnantwhiletakingthisdrug,thepatientshouldbeapprisedofthepotentialhazardtoafetus.Inanembryofetaldevelopmentalstudy,pregnantratswereadministeredvincristinesulfateliposomeinjectionintravenouslyduringtheperiodoforganogenesisatvincristinesulfatedosesof0.022to0.09mg/kg/day.Drugrelatedadverseeffectsincludedfetalmalformations(skeletalandvisceral),decreasesinfetalweights,increasednumbersofearlyresorptionsandpostimplantationlosses,anddecreasedmaternalbodyweightsMalformationswereobservedatdoses?0.044mg/kg/dayinanimalsatsystemicexposuresapproximately2040%ofthosereportedinpatientsattherecommendeddose. 8.3 NursingMothersItisnotknownwhetherthisdrugisexcretedinhumanmilk.Becausemanydrugsareexcretedinhumanmilkandbecauseofthepotentialforseriousadversereactionsinnursinginfants,adecisionshouldbemadewhethertodiscontinuenursingordiscontinuethedrugtakingintoaccounttheimportanceofthedrugtothemother. 8.4 PediatricUseThesafetyandeffectivenessofMarqiboinpediatricpatientshavenotbeenestablished. Reference ID: 3172211
 10                 1.14Labeling 8.5 GeriatricUseSafetyandeffectivenessinelderlyindividualshavenotbeenestablished. Ingeneral,doseselectionforanelderlypatientshouldbecautious,reflectingthegreaterfrequencyofdecreasedhepatic,renal,orcardiacfunction,andofconcomitantdiseaseorotherdrugtherapy. 8.6 RenalImpairmentTheinfluenceofrenalimpairmentonthesafety,efficacy,andpharmacokineticsofMarqibohasnotbeenevaluated. 8.7 HepaticImpairmentNonliposomalvincristinesulfateisexcretedprimarilybytheliver.TheinfluenceofseverehepaticimpairmentonthesafetyandefficacyofMarqibohasnotbeenevaluated. ThepharmacokineticsofMarqibowasevaluatedinpatientswithmoderatehepaticdysfunction(ChildPughB)secondarytomelanomalivermetastases.Thedoseadjustedmaximumplasmaconcentration(Cmax)andareaundertheconcentrationtimecurve(AUC)ofMarqiboinpatientswithmoderatehepaticimpairmentwascomparabletotheCmaxandAUCofpatientswithALLwhohadotherwisenormalhepaticfunction. 10 OVERDOSAGEWhenMarqibo(vinCRIStinesulfateLIPOSOMEinjection)wasadministeredatadoseof2.4mg/m2,severetoxicitiesincludingmotorneuropathyofGrade3,grandmalseizureofGrade4,andelevatedaspartateaminotransferaseandhyperbilirubinemiaofGrade4werereportedin1patienteach.Thereisnoknownantidoteforoverdosage. 11 DESCRIPTIONMarqibo(vinCRIStinesulfateLIPOSOMEinjection)isvincristineencapsulatedinsphingomyelin/cholesterolliposomesforintravenousadministration. TheactiveingredientinMarqiboisvincristinesulfate.Vincristinesulfateisavincaalkaloidisolatedasa1:1sulfatesaltfromtheperiwinkleplant(Catharanthus roseus). Itisahygroscopic,whitetoslightlyyellowishcrystallinepowderthatissolubleinwater.Ithasamolecularweightof923.04(saltform)/824.98(baseform)andamolecularformulaofC46H56N4O10&#x2022;H2SO4. Thechemicalnameforvincristinesulfateis22oxovincaleukoblastineandithasthefollowingchemicalstructure: VincristineisencapsulatedinaSphingomyelin/Cholesterolliposome.Thelipidcomponentsintheliposomearesphingomyelinandcholesterolatamolarratioofapproximately60:40(mol:mol). Afterpreparation,eachvialofMarqibocontains5mgvincristinesulfate,500mgmannitol,73.5mgsphingomyelin,29.5mgcholesterol,36mgsodiumcitrate,38mgcitricacid,355mgsodiumphosphate,and225mgsodiumchloride. Reference ID: 3172211
 11                  1.14Labeling Marqibo(vinCRIStinesulfateLIPOSOMEinjection)appearsasawhitetooffwhite,translucentsuspension,essentiallyfreeofvisibleforeignmatterandaggregates,comprisedofsphingomyelin/cholesterolliposomes,withanapproximateliposomemeandiameterof100nm.Greaterthan95%ofthedrugisencapsulatedintheliposomes. TheMarqiboKitcomponentvialsforthepreparationofMarqibo(vinCRIStinesulfateLIPOSOMEinjection)include: x  VinCRIStineSulfateInjection,USP(5mg/5mL).EachVinCRIStineSulfateInjectionvialconsistsof5mg/5mLvincristinesulfate(whichisequivalentto4.5mg/5mLvincristinefreebase)and100mg/5mLmannitol. x  Sphingomyelin/CholesterolLiposomeInjection(103mg/mL).EachSphingomyelin/CholesterolLiposomeInjectionvialconsistsof73.5mg/mLsphingomyelin,29.5mg/mLcholesterol,33.6mg/mLcitricacid,35.4mg/mLsodiumcitrate,andnotmorethan0.1%ethanol. x  SodiumPhosphateInjection(355mg/25mL).EachSodiumPhosphateInjectionvialconsistsof355mg/25mLdibasicsodiumphosphateand225mg/25mLsodiumchloride. 12 CLINICALPHARMACOLOGY12.1 MechanismofActionMarqiboisasphingomyelin/cholesterolliposomeencapsulatedformulationofvincristinesulfate.Nonliposomalvincristinesulfatebindstotubulin,alteringthetubulinpolymerizationequilibrium,resultinginalteredmicrotubulestructureandfunction.Nonliposomalvincristinesulfatestabilizesthespindleapparatus,preventingchromosomesegregation,triggeringmetaphasearrestandinhibitionofmitosis. 12.3 PharmacokineticsTheplasmapharmacokineticsofMarqibowasinvestigatedin13adultpatientswithrelapsedALLwhoreceivedaMarqibodoseof2.25mg/m2administeredasa1hourintravenousinfusion.ThecalculatedpharmacokineticparametersfortotalplasmavincristinesulfatearegiveninTable3. ThevincristinesulfatelevelsreportedinTable3reflectliposomeencapsulateddrugthatmaynotbeimmediatelybioavailableandmaynotbedirectlycomparabletoplasmalevelsofvincristinesulfateafteradministrationofnonliposomalvincristinesulfate,whichisimmediatelybioavailable. Table3. PharmacokineticParametersfromPatientswithAcuteLymphoblasticLeukemiaTreatedwith2.25mg/m2Marqiboa Variable N Mean SE Median RangeAUC' 13 14566 1766 13680 703626074(h&#x2022;ng/mL)CL 12 345 100 302 148783(mL/h)Cmax 13 1220 64 1230 9191720(ng/mL)a Dosewasadministeredasa1hourinfusion. Theplasmaclearance(CL)ofMarqiboisslow,345mL/h,atadoseof2.25mg/m2. Thisisincomparisontotherapidclearanceofnonliposomalvincristinesulfateat189mL/min/m2(11,340mL/h).TheslowclearanceofMarqibocontributestoamuchhigherAUCforMarqiborelativetononliposomalvincristinesulfate. Reference ID: 3172211
 12            1.14Labeling FollowingintravenousadministrationofMarqibo,urinaryexcretionwasaminorrouteofeliminationforvincristinesulfateanditsmetabolite.Lessthan8%oftheadministeredMarqibodosewaseliminatedinurineovera96hourobservationperiod,whichissimilartotheurinaryexcretionofnonliposomalvincristinesulfate.Followingnonliposomalvincristinesulfateinfusion,themainrouteofvincristinesulfateexcretionwasthefecalroute,accountingfor69%oftheadministereddoseover72hours. 13 NONCLINICALTOXICOLOGY13.1 Carcinogenesis,Mutagenesis,ImpairmentofFertilityNocarcinogenicitystudieshavebeenconductedwithMarqiboornonliposomalvincristinesulfate.Basedonthemechanismofactionandgenotoxicityfindingsinnonclinicalstudiesconductedwithnonliposomalvincristinesulfate,Marqibomaybecarcinogenic. NogenotoxicitystudieshavebeenconductedwithMarqibo.Nonliposomalvincristinewasgenotoxicinsomein vitroandin vivostudies.ThesingleandrepeatdoseanimaltoxicologystudyresultsindicatethatMarqibocanimpairmalefertility,consistentwiththeliteratureonnonliposomalvincristinesulfate.Administrationofvincristineliposomeinjectioncausestesticulardegenerationandatrophy,andepididymalaspermiainrats. Gonadaldysfunctionhasbeenreportedinbothmaleandfemalepostpubertalpatientswhoreceivedmultiagentchemotherapyincludingnonliposomalvincristinesulfate.Thedegreetowhichtesticularorovarianfunctionsareaffectedisage,dose,andagentdependent.Recoverymayoccurinsomebutnotallpatients. 13.2 AnimalToxicologyand/orPharmacologyInarepeatdosecomparativetoxicologystudyinrats,vincristinesulfateliposomeinjectionornonliposomalvincristinesulfatewasadministeredtoanimalsintravenouslyonceperweekfor6weeks.Clinicalsignsoftoxicityconsistentwithneurotoxicityweregreaterwithvincristinesulfateliposomeinjectionthanwithnonliposomalvincristinesulfateatequalvincristinesulfatedosesof2mg/m2/weekandincludeduncoordinatedmovements,weakness,reducedmuscletone,andlimitedusageofthelimbs.Neurologicaltestingindicateddruginducedperipheralneurotoxicitywithbothdrugs.Basedonthehistopathologyexaminationafter6weeklydoses,vincristinesulfateliposomeinjectioninducedgreaterperipheralneurotoxicity(nervefiberdegeneration)andsecondaryskeletalmuscleatrophythantheequaldoseofnonliposomalvincristinesulfate.Inaseparatetissuedistributionstudyinrats,administrationof2mg/m2ofintravenousliposomalornonliposomalvincristinesulfateshowedgreateraccumulationofvincristinesulfateinsciaticandtibialnerves(aswellasthelymphnodes,spleen,andbonemarrow)oftheanimalsfollowingvincristinesulfateliposomeinjection. 14 CLINICALSTUDIES14.1 AcuteLymphoblasticLeukemiaMarqibowasstudiedinaninternational,openlabel,multicenter,singlearmtrial(Study1).Eligiblepatientswere18yearsofageorolderwithPhiladelphiachromosomenegativeALLinsecondorgreaterrelapseorwhosediseaseprogressedaftertwoorgreatertreatmentlinesofantileukemiatherapy.Patientshadtohaveachievedacompleteremission(CR)toatleastonepriorantileukemiachemotherapy,definedbyaleukemiafreeintervalofequalormorethan90days.Patientswerenoteligibleforimmediatehematopoieticstemcelltransplantation(HSCT)atthetimeofscreeningandenrollment. PatientsreceivedintravenousMarqibomonotherapyat2.25mg/m2over60minutesevery7days.ConcomitantcorticosteroidswerenotpermittedbeyondDay5. Thetreatedpopulationincluded65patientswhoreceivedatleast1doseofMarqibo.Allofthetreatedpatientshadreceivedpriorvincristinesulfateand80%hadevidenceofresidualneuropathyatstudybaseline.Amongtreatedpatients,51%weremale,86%werewhite,45%wereunder30yearsofage,11%wereage65orolder, 13 Reference ID: 3172211
                           1.14Labeling 48%hadundergonepriorHSCT,51%hadreceived3ormorepriortherapies,and45%wererefractorytotheirimmediatepriortherapy.Diseasecharacteristicswere85%precursorBcellALLand15%precursorTcellALL. Inaddition,22of65(34%)treatedpatientsdidnotreceiveasparaginaseproductspriortoenrollment.EfficacyresultsareshowninTable4. Table4. Study1ResultsStudy1(N=65)n(%) Completeremission(CR) 3(4.6)CRwithincompletebloodcountrecovery(CRi) 7(10.8) CR+CRi 10(15.4)(95%CIa) (7.6&#x2013;26.5) MEDIANDURATIONofCRorCRi: Days(95%CI)BasedonthefirstdateofCRorCRitothedateofthelast 28(7,36)availablehistologicassessmentofthesameresponse(n=8)BasedonthefirstdateofCRorCRitodateofdocumented 56(9,65)relapse,death,orsubsequentchemotherapiesincludinghematopoieticstemcelltransplant(HSCT)(n=10)a CI=Confidenceinterval(ClopperPearson). 15 REFERENCES1.
 NIOSHAlert:Preventingoccupationalexposuretoantineoplasticandotherhazardousdrugsin  healthcaresettings.2004.U.S.DepartmentofHealthandHumanServices,PublicHealthService,  CentersforDiseaseControlandPrevention,NationalInstituteforOccupationalSafetyandHealth, DHHS(NIOSH)PublicationNo.2004165.  2.
 OSHATechnicalManual,TED10.15A,SectionVI:Chapter2.ControllingOccupationalExposuretoHazardousDrugs.OSHA,1999.http://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html 3.
 AmericanSocietyofHealthSystemPharmacists.ASHPguidelinesonhandlinghazardousdrugs.AmJHealthSystPharm.(2006)63:11721193. 4.
 PolovichM,WhiteJM,KelleherLO(eds.)2005.Chemotherapyandbiotherapyguidelinesand recommendationsforpractice(2nd.ed.)Pittsburgh,PA:OncologyNursingSociety.
  16 HOWSUPPLIED/STORAGEANDHANDLINGTheMarqiboKit(NDC#2053632201)contains: x VialcontainingVinCRIStineSulfateInjection,USP5mg/5mL(1mg/mL)&#x2013;NDC#2053632301x VialcontainingSphingomyelin/CholesterolLiposomeInjection103mg/mL&#x2013;NDC#2053632401x VialcontainingSodiumPhosphateInjection355mg/25mL(14.2mg/mL)&#x2013;NDC#2053632501x FlotationRingx OverlabelforSodiumPhosphateInjectionvialcontainingconstitutedMarqibo(vinCRIStinesulfate LIPOSOMEinjection),5mg/31mL(0.16mg/mL)x InfusionBagLabel 14 Reference ID: 3172211
       1.14Labeling 16.1 StorageStoretheMarqiboKitintherefrigeratorat2Cto8C&#x2013;DoNotFreeze 17 PATIENTCOUNSELINGINFORMATIONPhysiciansareadvisedtodiscussthefollowingwithpatientspriortotreatmentwithMarqibo: ExtravasationTissueInjury: Advisepatientstoreportimmediatelyanyburningorlocalirritationduringoraftertheinfusion[see Warnings and Precautions (5.2)].AbilitytoDriveorOperateMachineryorImpairmentofMentalAbility: Marqibomaycausefatigueandsymptomsofperipheralneuropathy.Advisepatientsnottodriveoroperatemachineryiftheyexperienceanyofthesesymptoms[see Warnings and Precautions (5.3, 5.7)].Gastrointestinal/Constipation:PatientsreceivingMarqibomayexperienceconstipation.Advisepatientshowtoavoidconstipationbyadiethighinbulkfiber,fruitsandvegetables,andadequatefluidintakeaswellasuseofastoolsoftener,suchasdocusate.Instructpatientstoseekmedicaladviceiftheyexperiencesymptomsofconstipationsuchbowelmovementinfrequency,abdominalpain,bloating,diarrhea,nausea,orvomiting[see Warnings and Precautions (5.6)].Pregnancy/Nursing:AdvisepatientstouseeffectivecontraceptivemeasurestopreventpregnancyduringtreatmentwithMarqibo[see Warnings and Precautions (5.9)]. Instructpatientstoreportpregnancytotheirphysiciansimmediately. AdvisepatientsthattheyshouldnotreceiveMarqibowhilepregnantorbreastfeeding.Ifapatientwishestorestartbreastfeedingaftertreatment,sheshouldbeadvisedtodiscusstheappropriatetimingwithherphysician[see Use in Specific Populations (8.3)].ConcomitantMedications:Advisepatientstospeakwiththeirphysiciansaboutanyothermedicationtheyarecurrentlytaking[see Drug Interactions (7)].PeripheralNeuropathy:Advisepatientstocontacttheirphysiciansiftheyexperienceneworworseningsymptomsofperipheralneuropathysuchastingling,numbness,pain,aburningfeelinginthefeetorhands,orweaknessinthefeetorhands[see Warnings and Precautions (5.3)].Other:Instructpatientstonotifytheirphysiciansiftheyexperiencefever,productivecough,ordecreasedappetite[see Warnings and Precautions (5.4)]. Reference ID: 3172211
 15      1.14Labeling Manufacturedby:VinCRIStineSulfateInjection,USPHospiraAustraliaPtyLtdMulgrave,Victoria3170Australia Sphingomyelin/CholesterolLiposomeInjectionCangeneCorporationWinnipeg,ManitobaR3T5Y3Canada SodiumPhosphateInjectionJubilantHollisterStierSpokane,WA99207 MarqiboKitforthePreparationofvinCRIStinesulfateLIPOSOMEinjectionAndersonPackaging,IncRockford,IL61109 Distributedby:TalonTherapeutics,Inc.400OysterPointBoulevard,Suite200SouthSanFrancisco,CA94080 Reference ID: 3172211
 16                                         PatientInformation  Marqibo(marKEYbo)  (vinCRIStinesulfateLIPOSOMEinjection)  ReadthisPatientInformationbeforeyoubeginreceivingMarqiboandbeforeeachMarqiboinfusion.Theremaybenewinformation.Thisinformationdoesnottaketheplaceofyoutalkingwithyourdoctoraboutyourmedicalconditionortreatment. WhatisMarqibo MarqiboisaprescriptionmedicineusedtotreatadultswithPhiladelphiachromosomenegative(Ph)acutelymphoblasticleukemia(ALL)when: x  theirleukemiahascomeback(relapsed)after2ormoreantileukemiatherapies,or x  theirleukemiabecameworse(progressed)aftertwoormoreantileukemiatherapies. ItisnotknownifMarqiboissafeandeffectiveinchildrenorinelderlyadults. DonotreceiveMarqibo: x  ifyouhavecertainconditionsofthebrainorspinalcord,includingCharcotMarieToothsyndrome.TalktoyourdoctorbeforereceivingMarqiboifyouhaveaconditionthataffectsyourbrainorspinalcord. x  ifyouareallergictovincristinesulfateoranyoftheingredientsinMarqibo.SeeendofthisleafletforalistoftheingredientsinMarqibo. x  asaninjectionintoyourspine(intrathecal). Marqibocausesdeathifgivenbyanyrouteotherthanbyintravenous(IV)infusion. WhatshouldItellmydoctorbeforereceivingMarqibo? BeforereceivingMarqibo,tellyourdoctorifyou: x  havehadtreatmentcontainingvincristinesulfateinthepastx  currentlyhavenumbnessortinglinginyourfeetorhandsordecreased sensitivitytoheat,cold,orpain x  havedifficultywalkingorpickingupandholdingitemswithyourhandsx  haveachangeinbowelregularityorconstipation,anddifficultypassingurinex  haveheadorjawpainx  haveliverproblemsx  arepregnantorplantobecomepregnant.Marqibocanharmyourunborn baby.YoushouldnotbecomepregnantwhiletakingMarqibo. UseaneffectivemethodofbirthcontrolduringtreatmentwithMarqibo. TellyourdoctorrightawayifyoubecomepregnantwhiletakingMarqibo. 1  Reference ID: 3172211
                                  x  arebreastfeedingorplantobreastfeed.
ItisnotknownifMarqibopassesintoyourmilk.YouandyourdoctorshoulddecidewhetheryouwilltakeMarqiboorbreastfeed.Youshouldnotdoboth. Tellyourdoctoraboutallthemedicinesyoutake,includingprescriptionandnonprescriptionmedicines,vitamins,andherbalsupplements.Marqibomayaffectthewayothermedicineswork,andothermedicinesmayaffecthowMarqiboworks. Knowthemedicinesyoutake.Keepalistofthemtoshowyourdoctorandpharmacistwhenyougetanewmedicine. HowwillIreceiveMarqibo? x  YouwillreceiveMarqiboasanintravenous(IV)infusioninyourveinover1hour.Marqiboisusuallygivenevery7days. x  Yourdoctormaychangeyourdose,giveyouMarqibolessoften,orstopyourtreatmentwithMarqiboifyouhavecertainsideeffects. x  YourdoctorshoulddobloodtestsregularlytocheckforsideeffectsofMarqibo. WhatshouldIavoidwhilereceivingMarqibo? x  Marqibocancausetiredness(fatigue)andnerveproblems(neuropathy).Youshouldnotdriveoroperatemachineryifyoudevelopanyofthesesymptoms.See&#x201c;WhatarethepossiblesideeffectsofMarqibo?&#x201d; WhatarethepossiblesideeffectsofMarqibo? Marqibocancauseserioussideeffects,including: x  Tissueinjury.IfMarqiboleaksfromyourveinintothetissuesaroundyourintravenous(IV)line,itcancausedamagetothosetissues.Tellyourdoctorornurserightawayifyoudevelopburning,rednessorswellingatyourIVsiteduringorafteryourinfusion. x  Nerveproblems(neuropathy). NerveproblemsarecommonwithMarqiboandmaygetworseovertime.Yourdoctormayneedtochangeyourdose,ordelayorstopyourtreatmentwithMarqiboifyoudevelopnerveproblems.Symptomsmayinclude: x  numbnessandtingling,orburninginyourfeetorhandsx  increasedordecreasedfeelingofsensationtopain,touch,heat,or coldinyourfeetorhandsx  jointandmusclepainx  paininyourjaworheadx  musclespasmsx  weaknessinthehandsorfeet 2  Reference ID: 3172211
                                                 x  dizzinessorfeelfaintwhenyougofromlyingdowntositting,orfromsittingtostanding. x  troublepickinguporholdingitemswithyourhandsx  slappingordroppingofthefrontpartofyourfootwhenwalking forward(footdrop)x  unsteadinesswhenstandingorwalkingx  difficultyspeakingx  constipationorachangefromthenormalregularityofyourbowel movementsx  difficultypassingurinex  difficultywitherectionorejaculationinmen x  Lowbloodcellcounts.
Marqibomaycauseyoutohavelowredbloodcells(anemia),lowwhitebloodcells(neutropenia),andlowplatelets(thrombocytopenia).YourdoctorshoulddobloodteststocheckyourbloodcellcountsbeforeeachdoseofMarqibo.YourdoctormayneedtochangeyourdoseofMarqiboandtreatyourlowbloodcellcountsifneeded. Tellyourdoctorifyoudevelopfeverorcoughupphlegm(productivecough). x  Tumorlysissyndrome(TLS).TLSiscausedbyafastbreakdownofcancercells.TLScancauseyoutohave: x  kidneyfailureandtheneedfordialysistreatmentx  anabnormalheartbeat YourdoctorwillcheckyouforTLSduringtreatmentwithMarqibo,andtreatyouforthisproblemifithappens. x  Constipationandintestinal(bowel)blockage.Yourdoctorwillprescribeabowelregimenforyoutohelppreventconstipationorintestinalblockage.Symptomsmayinclude: x  stomacharea(abdomen)pain,bloatingordiarrheax  nauseaorvomiting x  Tiredness(fatigue). Marqibocancauseseveretirednessorweariness.Yourdoctormayneedtochangeyourdose,ordelayorstopyoutreatmentifthishappens. x  Liverproblemsthatcancausedeath.Marqibocancausechangesinliverfunctiontestsormoreseriousliverproblemsthatcancausedeath.Yourdoctor: x  willmonitoryourliverfunctiontestduringtreatmentwithMarqibo.x  maychangeyourdoseorstopyourtreatmentwithMarqiboifyou developliverproblems. 3  Reference ID: 3172211
                      CommonsideeffectsofMarqiboinclude: x nauseax feverx diarrheax decreasedappetitex sleepproblems Tellyourdoctorifyouhaveanysideeffectthatbothersyouorthatdoesnotgoaway. ThesearenotallthepossiblesideeffectofMarqibo.Formoreinformation,askyourdoctororpharmacist. Callyourdoctorformedicaladviceaboutsideeffects.YoumayreportsideeffectstoFDAat1800FDA1088. GeneralinformationaboutMarqibo MedicinesaresometimesprescribedforpurposesotherthanthoselistedinaPatientInformationleaflet.ThisleafletsummarizesthemostimportantinformationyouneedtoknowaboutMarqibo. IfyouwouldlikemoreinformationaboutMarqibo,talkwithyourdoctor.
YoucanaskyourpharmacistordoctorforinformationaboutMarqibothatiswrittenforhealthprofessionals.Formoreinformation,gotowww.MarqiboRX.comorcall18882929617. WhataretheingredientsinMarqibo? Activeingredient:vincristinesulfate  Inactiveingredients:mannitol,sphingomyelin,cholesterol,sodiumcitrate, citricacid,sodiumphosphateandsodiumchloride. ThisPatientInformationhasbeenapprovedbytheU.S.FoodandDrugAdministration. Distributedby: TalonTherapeutics,Inc. SouthSanFrancisco,CA94080  IssuedAugust2012  Reference ID: 3172211
 4
  